Peter M Fischer
Affiliation: University of Nottingham
Soukarieh F, Nowicki M, Bastide A, Pöyry T, Jones C, Dudek K, et al
. Design of nucleotide-mimetic and non-nucleotide inhibitors of the translation initiation factor eIF4E: Synthesis, structural and functional characterisation. Eur J Med Chem. 2016;124:200-217 pubmed publisher
..Collectively, the data we present on structure-based design of eIF4E cap-binding inhibitors should facilitate the optimisation of such compounds as potential anticancer agents. ..
Fischer P. Turning down tau phosphorylation. Nat Chem Biol. 2008;4:448-9 pubmed publisher
..In vivo pharmacological inhibition of tau deglycosylation may be a new way to suppress abnormal tau phosphorylation, known to be involved in the formation of neurofibrillary tangles in the brain. ..
Jadhav G, Kaur I, Maryati M, Airhihen B, Fischer P, Winkler G. Discovery, synthesis and biochemical profiling of purine-2,6-dione derivatives as inhibitors of the human poly(A)-selective ribonuclease Caf1. Bioorg Med Chem Lett. 2015;25:4219-24 pubmed publisher
..Two Mg(2+) ions present in the active sites of these ribonucleases are required for RNA cleavage. Here, we report the discovery, synthesis and biochemical profiling of purine-2,6-dione derivatives as (sub)micromolar inhibitors of Caf1. ..
Baker J, Gardiner S, Woolard J, Fromont C, Jadhav G, Mistry S, et al
. Novel selective ?1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. FASEB J. 2017;31:3150-3166 pubmed publisher
..M., Woolard, J., Fromont, C., Jadhav, G. P., Mistry, S. N., Thompson, K. S. J., Kellam, B., Hill, S. J., Fischer, P. M. Novel selective ?1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. ..
Fischer P. Cap in hand: targeting eIF4E. Cell Cycle. 2009;8:2535-41 pubmed
..The emerging understanding of the functions, regulation, and structural biology of eIF4E now makes possible the pharmacological targeting of this key translation initiation factor. ..